Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Below are the small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue. The trailing-twelve-month revenue at Abaxis

is $187.18 million. Abaxis's ROE for the same period is 16.18%. The trailing-twelve-month revenue at Meridian Bioscience

is $184.04 million. Meridian Bioscience's PEG ratio is 2.00. The trailing-twelve-month revenue at Quidel

is $177.42 million. Quidel's operating margin for the same period is 13.34%. The trailing-twelve-month revenue at Trinity Biotech plc

is $86.58 million. Trinity Biotech had $26.81 million in total cash for the latest quarter.